Slide 1: Welcome to the 2Q22 Webinar
Welcome to the 2Q22 Webinar modulight
Slide 2: Today’s agenda
Today’s agenda ❑ 2Q22 key messages ❑ Financials ❑ Operating environment ❑ Progress highlights ❑ Project pipeline ❑ Strategy update ❑ Q&A Memorial Sloan Kettering, New York (Jul-22) 2
Slide 3: 2Q22 key messages
❑ Continued the execution of the growth strategy and investments in production capacity. ❑ Good progress with some projects, total number of projects 26 (1Q22: 26). A major new order announced in April (USD 3.9 million), several smaller ones during the quarter ❑ Financial performance disappointing,
Slide 4: Key figures
Key figures Key Figures1) (thousand euro, unless stated otherwise) 1-6/2022 1-6/2021 4-6/2022 4-6/2021 1-12/20212) Revenue 2,100 4,560 498 2,355 9,071 EBITDA -2,594 3,158 -2,176 1,784 461 EBITDA-% -123.5 % 69.2 % -436.8 % 75.7 % 5.1 % Operating result (EBIT) -3,480 2,605 -2,610 1,482 - 753 Operating
Slide 5: Long-term growth drivers in the market
Long-term growth drivers in the market Oncology (cancer diseases) Ophthalmological diseases Genetics and Diagnostics Market size billion. $ 1 Market size billion $ 2 Market size billion $ 3 391 29,5 48 21,2 144 2019 2030 forecast 2018 2026 ennuste 2020 2028 ennuste Main growth factor: Aging populati
Slide 6: Short-term operation environment
Short-term operation environment COVID-19 related Global problems with basic Macroeconomic and restrictions related to component availability geopolitical uncertainty traveling and on-site visits which postponed about half impacts some customers’ slow down our customers’ of our planned second- capit
Slide 7: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts principle, share of pharmaceutical or treatment without revenue risk for Modulight fees, or the utilization rate of industrial applications. Current pharmaceutical and biomedical projects are mostl
Slide 8: Progress highlights from 2Q22
Progress highlights from 2Q22 A major new order IP portfolio A new analytics Continued expansion (USD 3.9 million) and strengthened and team is also working of manufacturing several smaller ones three new US patents on several new capacity and during the quarter. filed during the patent applications
Slide 9: Project portfolio remains solid
Project portfolio remains solid Total number of project with commercialization potential 25 Change since previous quarter 20 15 10 5 0 1Q19 1Q19 2Q19 2Q19 3Q19 3Q19 4Q19 4Q19 1Q20 1Q20 2Q20 2Q20 3Q20 3Q20 4Q20 4Q20 1Q21 1Q21 2Q21 2Q21 3Q21 3Q21 4Q21 4Q21 1Q22 1Q22 2Q22 2Q22 9
Slide 10: Modulight’s customer base – pipeline projects
Modulight’s customer base – pipeline projects Ownership Maturity Size 30 30 30 25 25 25 20 20 20 15 15 15 10 10 10 5 5 5 0 0 2Q21 3Q21 4Q21 1Q22 2Q22 2Q21 3Q21 4Q21 1Q22 2Q22 0 2Q21 3Q21 4Q21 1Q22 2Q22 Listed company Research Research Private companies Other companies Early stage Blue chip Establish
Slide 11: New projects started in 1H22
New projects started in 1H22 Customer: One of the worlds five largest Customer: established US public Customer: established company pharmaceutical companies company Indication: Using clinical laser for developing Indication: New dermatology therapy Indication: Ophthalmology a new treatment modality
Slide 12: Updated strategy to be announced later this year
Updated strategy to be announced later this year ❑ Modulight’s unique technology is the basis for our long-term success. ❑ Significant opportunities seen in expanding our co-operation with existing blue chip & established company customers and offering our technology to new customers, applications a
Slide 13: Previously communicated strategic key factors
Previously communicated strategic key factors Strategic Key Factors Increasing Geographical Expanding the Opportunities for Continuous production expansion product range expansion in the investments in capacity other indications field of cloud software & laser analytics technology Modulight plans to
Slide 14: Outlook updated
Outlook updated New outlook Previous outlook (announced on April 28, 2022): Modulight has not issued a guidance for revenue or profitability in 2022. Modulight has not issued a guidance for revenue or profitability in 2022. As the company’s customer projects are still distributed across varying earl
Slide 15: Thank you! Questions?
Thank you! Questions? LEARN MORE AND FOLLOW US IN TWITTER, FACEBOOK, YOUTUBE AND INSTAGRAM: 15
Slide 16: Strengths
Strengths 1 2 3 4 5 – – – – – Over 20 years of Scalability and A significant Significant Strong financial experience in better clientele business performance. medical and laser therapeutic consisting of opportunities technology performance well-known offered by the enabled by pharmaceutical pharmace
Slide 17: Previously communicated targets
Previously communicated targets Long Term Objectives Dividend Policy Business Objective: Financial Objectives: Proceed to large-scale Maintain strong Maintain strong In the coming years, Modulight commercial deployment1 with revenue growth profitability will focus on financing the company’s three cu
Slide 18: Modulight in brief
Modulight in brief Modulight provides lasers and optics for demanding applications EBITDA, % average 44 % 2018-2021 Medicine- ja Biomedicine Other high-value add applications Projects with • Oncology (cancer diseases) • Modulight provides laser • Quantum computing commercialization products solution
Slide 19: A significant customer base
A significant customer base, consisting of well-known pharmaceutical and technology companies Medicine and Biomedicine Other high-value add applications Modulight’s customer base on medical and biomedical industries Modulight’s customer base on other high-value include well-known hospitals, universi
Slide 20: A typical project
A typical project CASE EXAMPLE: Generic Modulight customer project flow Customer contacts Modulight 6 – 24 months 3 – 5 years 5 – 10 years Sales cycles vary – Typical projects Project plans are often ambitious - New cancer GTM phase – often months start with early delays are common due to many thera